Europe
Bristol-Myers Squibb is teaming up with Cancer Research UK and the Francis Crick Institute to create guidelines for immuno-oncology therapy development. This “rule book,” will focus on lung cancer treatments.
As Britain continues to move forward with its plans to leave the European Union, a new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.
an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk patients) and show a favorable and distinct treatment strategy for the low and high-risk patients in an interim data analysis.
In the framework of a preferred partnership, Yposkesi plans to grant Axovant access to dedicated cGMP capacity and manufacturing resources to further support the global development and commercialization of Axovant’s AAV-based gene therapy programs
HEMOBLAST Bellows now used in 26 US hospitals and under evaluation in more than 240 hospitals, a strong sign of market adoption
Galapagos NV announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA).
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. Although most readers will already be aware of it, the biggest story, perhaps the biggest story of the year—certainly the most controversial—involves a Chinese researcher who used CRISPR to modify embryos to be resistant to HIV, and the recent birth of a set of twins.
Bayer will cut 12,000 jobs as it prepares an overhaul of its business that includes exiting its animal health business as it deals with the fallout from its $63 billion acquisition of Monsanto. Additionally, the company said it will sell its 60 percent stake in Germany-based site services provider Currenta.
Alkermes, headquartered in Dublin, announced positive topline data from ENLIGHTEN-2, its pivotal Phase III trial of ALKS 3831 (olanzapine/samidorphan) for schizophrenia.
It is anticipated that this initial concept will be scaled to all UK biobanks and genomic cohorts and will be replicated across European countries wanting to adopt the UK model through working with European organisations such as BBMRI-ERIC and ELIXIR.
PRESS RELEASES